IMB Dx

What IMB Dx does

IMB Dx (IMBdx Inc.) is a Seoul-headquartered precision oncology company founded in 2018 by academic oncologist Tae-You Kim (former director of Seoul National University Cancer Hospital) and Yonsei University chemist Duhee Bang. The company operates a CAP-accredited clinical laboratory and commercializes a liquid biopsy platform based on circulating tumor DNA (ctDNA) analysis using next-generation sequencing. Its technology stack combines targeted hybrid capture sequencing (HQS), whole-genome methylation sequencing, fragmentomics, copy number variation analysis, and proprietary AI/ML models to deliver three product lines: AlphaLiquid 100/HRR for comprehensive tumor genomic profiling of solid tumors across up to 192 genes; CancerDetect for tumor-informed minimal residual disease (MRD) monitoring with a reported limit of detection of 0.001% ctDNA; and CancerFind, a blood-based multi-cancer early-detection test covering up to 12 cancer types. Supporting offerings include a whole-exome sequencing-based HRD assay (CancerProfiler) and analytical services running on a cloud-based remote testing model.

IMB Dx generates revenue through (i) fee-for-service clinical NGS testing on samples sent by ~37 major Korean hospitals and international partners, (ii) cancer screening tests supplied to ~103 Korean screening centers, (iii) companion diagnostic and clinical-trial-support services for biopharmaceutical companies (including an AstraZeneca collaboration for prostate cancer HRR testing), and (iv) cloud-based remote bioinformatics services for partner laboratories. The company is publicly listed on KOSDAQ (ticker 461030), following an April 2024 IPO that set the highest competition ratio (2,654.20:1) in Korean biotech IPO history, and operates branch offices in Tokyo, Japan. AlphaLiquid 100 carries CE-IVD marking, CancerDetect received Korean Innovative Medical Technology designation in 2025, and the company holds GMP, ISO 13485, and Taiwan SNQ certifications.

Customer concentration is moderate-to-low at the account level (~37 anchor hospital accounts domestically plus a long tail of ~103 screening centers) but entirely within a single vertical (oncology/healthcare). Geographic expansion to approximately 20 countries is executed primarily through channel partners (notably MedPeer in Japan reaching 170,000 physicians) rather than wholly owned sales infrastructure, which limits direct revenue capture abroad but accelerates footprint growth.

Name

IMB Dx

Legal name

(주)아이엠비디엑스

Website

https://imbdx.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

IMB Dx is a Seoul-based, KOSDAQ-listed precision oncology company operating a CAP-accredited liquid biopsy platform (ctDNA/NGS) that delivers tumor profiling (AlphaLiquid), MRD monitoring (CancerDetect), and 12-cancer multi-cancer screening (CancerFind) to major Korean hospitals, screening centers, and international biopharma and channel partners.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAAALAE

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAAANAG

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing

Healthcare & Life Sciences/Biotechnology & Biologics/Precision Medicine Solutions

SECONDARYHLAHAAAJ

Companion Diagnostics (CDx) & Precision Medicine IVD

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

SECONDARYHLAAALAN

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAAAMAH

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

• Liquid biopsy diagnostics
• Circulating tumor DNA analysis
• Cancer genomic profiling
• Minimal residual disease monitoring
• Multi-cancer early detection

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Testing Services (Laboratory Developed Tests): IMB Dx provides clinical laboratory testing services for cancer patients through its CAP-accredited laboratory. Hospitals and clinics collect patient blood/fluid samples and send them to IMB Dx for NGS analysis, with results returned to treating physicians for treatment decision-making.
2. Companion Diagnostics for Pharmaceutical Companies: IMB Dx provides liquid biopsy-based companion diagnostic services for biopharma companies in clinical trials, including customized panel design and genomic profiling to support drug development and patient stratification.
3. Cancer Screening Tests (CancerFind): Direct-to-institution supply of multi-cancer early screening tests (CancerFind) to hospitals and screening centers for general population use, generating revenue per test performed.
4. Cloud-Based Remote Testing: Remote testing service where local labs perform NGS workflow and sequencing, with data transferred to IMB Dx's secure cloud platform for bioinformatics analysis and clinical report generation.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

IMB Dx operates a CAP-accredited clinical laboratory that provides NGS-based liquid biopsy services through its proprietary AlphaLiquid® platform, analyzing circulating tumor DNA (ctDNA) from blood and other body fluids. Its three commercial offerings are AlphaLiquid 100 (comprehensive genomic profiling of solid tumors covering ~118–192 genes), CancerDetect™ (ultra-sensitive minimal residual disease monitoring with 0.001% LoD), and CancerFind™ (multi-cancer early screening across up to 12 cancer types from a single blood draw). The company supplies these tests to hospitals, screening centers, and biopharma partners in Korea and internationally.

Differentiator

Problem solved

Functional benefit

Products and services

• AlphaLiquid 100 / AlphaLiquid 3.0 (CancerDx200) NGS-based comprehensive genomic profiling liquid biopsy service for solid tumors, analyzing ctDNA from blood and various body fluids (pleural effusion, ascites, cerebrospinal fluid, bronchial washing fluid). Used by oncologists for treatment matching, treatment response monitoring, and resistance mutation detection in advanced cancer patients. Includes the HRR gene panel (19 genes) for PARP inhibitor response prediction in ovarian and prostate cancers.
• CancerDetect™ Tumor-informed and tumor-agnostic minimal residual disease (MRD) liquid biopsy assay combining patient-specific bespoke mutations with tumor-agnostic clinically actionable hotspot mutations across 15 genes. Achieves a limit of detection of 0.001% ctDNA with 99.9% specificity for monitoring post-surgical recurrence risk in cancer patients.
• CancerFind™ Multi-cancer early screening blood test using whole-genome methylation sequencing combined with an AI ensemble model integrating methylation, CNV, fragment size ratio, and fragment size distribution. Screens for up to 12 cancer types (colorectal, gastric, liver, pancreatic, lung, breast, ovarian, prostate, kidney, bladder, cervical, endometrial) for asymptomatic and high-risk individuals.
• AlphaLiquid Breast Liquid biopsy genomic profiling assay dedicated to breast cancer, covering 25 key genes including ESR1, PIK3CA, AKT1, and PTEN to support treatment selection and resistance monitoring in breast cancer patients.
• Clinical Laboratory Testing Service CAP-accredited clinical laboratory service where hospitals and clinics submit patient blood or body fluid samples to IMB Dx for NGS-based ctDNA analysis, with results returned to treating physicians for clinical decision-making.
• Biopharma Companion Diagnostics Service Liquid biopsy-based companion diagnostic services for biopharma companies in clinical trials, including customized panel design, genomic profiling for patient stratification, biomarker discovery, and drug efficacy monitoring (e.g., partnership with AstraZeneca for HRR testing in prostate cancer).
• Cloud-Based Remote Testing Service Remote testing service where local laboratories perform the NGS workflow and sequencing on site, then transfer sequencing data to IMB Dx's secure cloud platform for bioinformatics analysis and clinical report generation. Enables global scaling without shipping samples to IMB Dx's headquarters laboratory.

Quantifiable outcome

• CancerDetect MRD-positive colorectal cancer patients showed 6.15x higher recurrence risk vs. MRD-negative patients in 809-patient prospective study
• +6 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Guardant Health: NASDAQ-listed U.S. leader in liquid biopsy with Guardant360 (tumor profiling) and Guardant Reveal (MRD); directly comparable to IMB Dx's AlphaLiquid 100 and CancerDetect, with established Japan presence and head-to-head performance reference cited by IMB Dx.
• Natera: NASDAQ-listed U.S. company with Signatera (tumor-informed MRD) and Empower (multi-cancer screening); directly comparable to CancerDetect and CancerFind with extensive MRD clinical evidence base and broad U.S. payer reimbursement.
• Foundation Medicine (Roche): Roche-owned comprehensive genomic profiling leader (FoundationOne CDx, FoundationOne Liquid CDx); directly competes in tumor profiling space where AlphaLiquid 100 is positioned and is the dominant CDx partner for global pharma.
• GRAIL (Illumina): Multi-cancer early detection (MCED) leader with Galleri test using methylation-based cfDNA analysis; directly comparable to CancerFind on technology architecture (whole-genome methylation + ML) and target use case (asymptomatic screening).
• Exact Sciences: U.S. cancer diagnostics leader with Cologuard (CRC screening) and Oncotype DX; comparable as a multi-product oncology diagnostics platform spanning screening, profiling, and treatment guidance, and a relevant benchmark for commercial scale and reimbursement.
• Burning Rock Biotech: China-based liquid biopsy company (NASDAQ:BNR) with NGS-based cancer profiling and MRD assays; closely comparable as an Asia-Pacific focused liquid biopsy platform with both clinical testing and biopharma CDx services.
• Singlera Genomics: China-based multi-cancer early detection company (ColonES, etc.) using cfDNA methylation sequencing; directly comparable to CancerFind in technology approach and Asia-Pacific cancer screening focus.

Broad incumbents

• NeoGenomics: U.S. oncology-focused clinical laboratory services company offering comprehensive cancer testing including liquid biopsy; comparable as a broader oncology diagnostics services provider with established hospital and biopharma channel relationships.

Regional players

• Genomedia: Korean molecular diagnostics company specializing in NGS-based cancer testing and biopharma CDx services; directly comparable as a Korea-based oncology diagnostics peer competing in the same hospital channels.

Emerging players

• AnchorDx: China-based liquid biopsy company focused on cancer screening and monitoring using methylation and cfDNA analysis; emerging player with comparable multi-cancer early detection technology architecture to CancerFind.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMB Dx